Digestive Diseases and Sciences

, Volume 40, Issue 6, pp 1360–1364 | Cite as

A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer

A multicenter trial
  • M. Cremer
  • R. Lambert
  • C. B. H. W. Lamers
  • G. Delle Fave
  • C. Maier
  • The European Pantoprazole Study Group
Esophageal, Gastric, And Duodenal Disorders

Abstract

Pantoprazole is a new substituted benzimidazole, which is a potent inhibitor of gastric acid secretion by its inhibition of H+,K+-ATPase. Pantoprazole, 40 mg, was compared with the H2-receptor antagonist ranitidine, 300 mg, in the healing of acute duodenal ulcer. Two hundred seventy-six patients with endoscopically diagnosed duodenal ulcer were studied in this multicenter double-blind study. Patients were reendoscopied after two weeks of treatment, and those patients whose ulcers remained unhealed were also endoscoped after an additional two weeks of treatment. The primary end point was the complete healing of the ulcer. Demographic characteristics were comparable in both treatment groups. After two weeks of treatment, 90/124 (73%) patients in the pantoprazole group had healed ulcers compared with 57/126 (45%) patients in the ranitidine group (P<0.001, per-protocol analysis). After four weeks, the cumulative healing rates were 92% and 84% in the pantoprazole and ranitidine groups, respectively (P=0.073). Symptoms were also improved at week 2, with 84% and 72% of patients in the pantoprazole and ranitidine groups, respectively, reporting no ulcer pain (P<0.05, per-protocol analysis). Both treatments were well tolerated. This study has confirmed the superiority of pantoprazole compared with ranitidine in the healing of duodenal ulcers and pain relief after two weeks of treatment and has shown pantoprazole to be well tolerated in this indication.

Key words

pantoprazole ranitidine duodenal ulcer multinational dosage 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kromer W, Postius S, Riedel R, Simon WA, Hanauer G, Brand U, Gönne S, Parson ME: BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J Pharmacol Exp Ther 254:129–135, 1990PubMedGoogle Scholar
  2. 2.
    Simon B, Müller P, Bliesath H, Lühmann R, Hartmann M, Huber R, Wurst W: Single intravenous administration of BY1023/SK&F 96022—inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4:239–245, 1990PubMedGoogle Scholar
  3. 3.
    Simon B, Müller P, Hartmann M, Bliesath H, Lühmann R, Huber R, Bohnenkamp W, Wurst W: Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+,K+-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. Z Gastroenterol 28:443–447, 1990PubMedGoogle Scholar
  4. 4.
    Simon B, Müller P, Marinis E, Lühmann R, Huber R, Hartmann M, Wurst W: Effect of repeated oral administration of BY1023/SK&F96022—a new substituted benzimidazole derivative—on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4:373–379, 1990PubMedGoogle Scholar
  5. 5.
    Reill L, Erhardt F, Fishcer R, Londong W: Intragastric pH and serum gastrin after one week of treatment with pantoprazole, ranitidine or placebo. Gastroenterology 104:A177, 1993 (abstract)Google Scholar
  6. 6.
    Hartmann M, Theiss U, Bliesath H, Wieckhorst G, Lühmann R, Wurst W, Postius S, Lücker PW: Comparison of the 24 h intragastric pH profiles following single and repeated oral intake of pantoprazole 40 mg and omeprazole 20 mg in healthy male volunteers. Gastroenterology 104:A95, 1993 (abstract)Google Scholar
  7. 7.
    Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW: Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther 32:385–399, 1994PubMedGoogle Scholar
  8. 8.
    Müller P, Simon B, Khalil H, Lühmann R, Leucht U, Schneider A: Dose-range finding study with the proton pump inhibitor, pantoprazole, in acute duodenal ulcer patients. Z Gastroenterol 30:771–775, 1992PubMedGoogle Scholar
  9. 9.
    Mulder CJJ, Schipper DL: Omeprazole and ranitidine in duodenal ulcer healing. Analysis of comparative clinical trials. Scand J Gastroenterol 25(suppl 178):62–66, 1990Google Scholar
  10. 10.
    McTavish D, Buckley MM-T, Heel RC: Omeprazole: An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 42:138–170, 1991PubMedGoogle Scholar
  11. 11.
    Londong W, Barth H, Dammann HG, Hengels KJ, Kleinert R, Müller P, Rohde H, Simon B: Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. Aliment Pharmacol Ther 5:245–254, 1991PubMedGoogle Scholar
  12. 12.
    Lloyd-Davies KA, Rutgersson K, Sölvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Aliment Pharmacol Ther 2:13–32, 1988PubMedGoogle Scholar
  13. 13.
    Gugler R, Hartmann M, Rudi J, Bliesath H, Brod I, Klotz U, Huber R, Steinijans VW, Wurst W: Lack of interaction of pantoprazole and diazepam in man. Z Gastroenterol 102(suppl):A77, 1992Google Scholar
  14. 14.
    Bader JP, Delchier JC: Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 8(suppl 1):47–52, 1994PubMedGoogle Scholar
  15. 15.
    Mignon M, Vallot T: Acute treatment of duodenal ulcer: experience with lansoprazole. Aliment Pharmacol Ther 7(suppl 1):37–40, 1993PubMedGoogle Scholar
  16. 16.
    Lanzon-Miller S, Pounder RE, Hamilton MR, Ball S, Chronos NAF, Raymond F, Olausson M, Cederberg C: Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1:329–251, 1987Google Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • M. Cremer
    • 1
    • 2
    • 3
    • 4
    • 5
  • R. Lambert
    • 1
    • 2
    • 3
    • 4
    • 5
  • C. B. H. W. Lamers
    • 1
    • 2
    • 3
    • 4
    • 5
  • G. Delle Fave
    • 1
    • 2
    • 3
    • 4
    • 5
  • C. Maier
    • 1
    • 2
    • 3
    • 4
    • 5
  • The European Pantoprazole Study Group
  1. 1.From Center 1, Hôpital ErasmeBrusselsBelgium
  2. 2.Center 2, Hépatogastroentérologie, Hôpital E. HerriotLyonFrance
  3. 3.Center 3, Department of Gastroenterology-HepatologyUniversity HospitalLeidenThe Netherlands
  4. 4.Center 4, Clinica Medica IIa, Policlinico Umberto IRomeItaly
  5. 5.Center 5, Department of Clinical ResearchByk GuldenKonstanzGermany

Personalised recommendations